Do analysts recommend NAGE or BYSI?

Niagen Bioscience presently has a consensus price target of $10.50, suggesting a potential upside of 206.57%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, research analysts plainly believe Niagen Bioscience is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate BYSI or SRZN?

Surrozen has a consensus price target of $42.00, suggesting a potential upside of 87.98%. Given Surrozen's stronger consensus rating and higher probable upside, analysts plainly believe Surrozen is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Surrozen 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is BYSI or SRZN more profitable?

BeyondSpring has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -14.00% Surrozen -4,810.50% N/A -154.08%

Do analysts rate NKTX or BYSI?

Nkarta presently has a consensus price target of $10.75, indicating a potential upside of 319.10%. Given Nkarta's stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nkarta 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NKTX or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -30.90% -24.20% BeyondSpring N/A N/A -14.00%

Do analysts prefer ACIU or BYSI?

AC Immune currently has a consensus target price of $7.50, indicating a potential upside of 235.57%. Given AC Immune's stronger consensus rating and higher possible upside, equities research analysts plainly believe AC Immune is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AC Immune 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ACIU or BYSI more profitable?

BeyondSpring has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. BeyondSpring's return on equity of 0.00% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -1,788.02% -125.26% -40.85% BeyondSpring N/A N/A -14.00%

Do analysts prefer BYSI or CHRS?

Coherus Oncology has a consensus price target of $8.67, indicating a potential upside of 499.77%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Coherus Oncology is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75

BeyondSpring (BYSI) Competitors

$1.23 -0.02 (-1.60%)

As of 11:29 AM Eastern

Compare

BYSI vs. NAGE, SRZN, NKTX, ACIU, and CHRS

Should you buy BeyondSpring stock or one of its competitors? MarketBeat compares BeyondSpring with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BeyondSpring include Niagen Bioscience (NAGE), Surrozen (SRZN), Nkarta (NKTX), AC Immune (ACIU), and Coherus Oncology (CHRS). These companies are all part of the "pharmaceutical products" industry.

How does BeyondSpring compare to Niagen Bioscience?

Niagen Bioscience (NASDAQ:NAGE) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Niagen Bioscience has higher revenue and earnings than BeyondSpring. BeyondSpring is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	2.11	$17.38M	$0.21	16.31
BeyondSpring	$1.75M	28.90	-$1.01M	-$0.14	N/A

Niagen Bioscience has a net margin of 14.29% compared to BeyondSpring's net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat BeyondSpring's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
BeyondSpring	N/A	N/A	-14.00%

In the previous week, Niagen Bioscience had 5 more articles in the media than BeyondSpring. MarketBeat recorded 5 mentions for Niagen Bioscience and 0 mentions for BeyondSpring. Niagen Bioscience's average media sentiment score of 0.38 beat BeyondSpring's score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Niagen Bioscience	Neutral
BeyondSpring	Neutral

Niagen Bioscience has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

Niagen Bioscience presently has a consensus price target of $10.50, suggesting a potential upside of 206.57%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, research analysts plainly believe Niagen Bioscience is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Niagen Bioscience beats BeyondSpring on 14 of the 17 factors compared between the two stocks.

How does BeyondSpring compare to Surrozen?

BeyondSpring (NASDAQ:BYSI) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

In the previous week, Surrozen had 2 more articles in the media than BeyondSpring. MarketBeat recorded 2 mentions for Surrozen and 0 mentions for BeyondSpring. Surrozen's average media sentiment score of 0.97 beat BeyondSpring's score of 0.00 indicating that Surrozen is being referred to more favorably in the news media.

Company	Overall Sentiment
BeyondSpring	Neutral
Surrozen	Positive

BeyondSpring has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Surrozen	-4,810.50%	N/A	-154.08%

BeyondSpring has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 29.3% of BeyondSpring shares are held by insiders. Comparatively, 31.7% of Surrozen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

BeyondSpring has higher earnings, but lower revenue than Surrozen. BeyondSpring is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	28.90	-$1.01M	-$0.14	N/A
Surrozen	$7.49M	34.61	-$242.03M	-$37.59	N/A

Surrozen has a consensus price target of $42.00, suggesting a potential upside of 87.98%. Given Surrozen's stronger consensus rating and higher probable upside, analysts plainly believe Surrozen is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Surrozen	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Surrozen beats BeyondSpring on 12 of the 16 factors compared between the two stocks.

How does BeyondSpring compare to Nkarta?

Nkarta (NASDAQ:NKTX) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

BeyondSpring's return on equity of 0.00% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
BeyondSpring	N/A	N/A	-14.00%

Nkarta presently has a consensus price target of $10.75, indicating a potential upside of 319.10%. Given Nkarta's stronger consensus rating and higher probable upside, analysts plainly believe Nkarta is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 9.8% of Nkarta shares are owned by insiders. Comparatively, 29.3% of BeyondSpring shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BeyondSpring has higher revenue and earnings than Nkarta. BeyondSpring is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
BeyondSpring	$1.75M	28.90	-$1.01M	-$0.14	N/A

Nkarta has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

In the previous week, Nkarta's average media sentiment score of 0.59 beat BeyondSpring's score of 0.00 indicating that Nkarta is being referred to more favorably in the media.

Company	Overall Sentiment
Nkarta	Positive
BeyondSpring	Neutral

Summary

Nkarta beats BeyondSpring on 8 of the 14 factors compared between the two stocks.

How does BeyondSpring compare to AC Immune?

AC Immune (NASDAQ:ACIU) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

BeyondSpring has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. BeyondSpring's return on equity of 0.00% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
BeyondSpring	N/A	N/A	-14.00%

BeyondSpring has lower revenue, but higher earnings than AC Immune. BeyondSpring is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	52.77	-$85.03M	-$0.82	N/A
BeyondSpring	$1.75M	28.90	-$1.01M	-$0.14	N/A

AC Immune has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

51.4% of AC Immune shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

AC Immune currently has a consensus target price of $7.50, indicating a potential upside of 235.57%. Given AC Immune's stronger consensus rating and higher possible upside, equities research analysts plainly believe AC Immune is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, AC Immune's average media sentiment score of 0.00 equaled BeyondSpring'saverage media sentiment score.

Company	Overall Sentiment
AC Immune	Neutral
BeyondSpring	Neutral

Summary

AC Immune beats BeyondSpring on 8 of the 14 factors compared between the two stocks.

How does BeyondSpring compare to Coherus Oncology?

BeyondSpring (NASDAQ:BYSI) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Coherus Oncology has a consensus price target of $8.67, indicating a potential upside of 499.77%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Coherus Oncology is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

BeyondSpring has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Coherus Oncology has higher revenue and earnings than BeyondSpring. BeyondSpring is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	28.90	-$1.01M	-$0.14	N/A
Coherus Oncology	$42.17M	5.29	$168.02M	$1.67	0.87

In the previous week, BeyondSpring's average media sentiment score of 0.00 equaled Coherus Oncology'saverage media sentiment score.

Company	Overall Sentiment
BeyondSpring	Neutral
Coherus Oncology	Neutral

Coherus Oncology has a net margin of 397.30% compared to BeyondSpring's net margin of 0.00%. BeyondSpring's return on equity of 0.00% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Coherus Oncology	397.30%	-198.90%	-46.65%

40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Coherus Oncology beats BeyondSpring on 10 of the 14 factors compared between the two stocks.

Get BeyondSpring News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BYSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BYSI vs. The Competition

Export

Metric	BeyondSpring	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$50.58M	$3.66B	$6.81B	$12.36B
Dividend Yield	N/A	2.18%	2.67%	9.67%
P/E Ratio	-8.79	20.61	26.84	24.01
Price / Sales	28.90	165.30	489.39	79.43
Price / Cash	10.91	150.24	49.71	59.37
Price / Book	-2.08	8.02	10.41	6.17
Net Income	-$1.01M	$23.81M	$3.60B	$331.82M
7 Day Performance	-3.15%	-3.15%	-1.81%	-1.62%
1 Month Performance	-23.84%	-0.54%	0.49%	-2.14%
1 Year Performance	-34.22%	41.55%	22.76%	17.56%

BeyondSpring Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BYSI BeyondSpring	0.0286 of 5 stars	$1.23 -1.6%	N/A	-33.5%	$50.58M	$1.75M	N/A	80	Positive News Gap Up
NAGE Niagen Bioscience	4.343 of 5 stars	$3.37 -2.3%	$10.50 +211.6%	-63.9%	$268.40M	$130.42M	16.05	120
SRZN Surrozen	3.0555 of 5 stars	$22.88 -0.6%	$42.00 +83.6%	+164.3%	$265.64M	$3.48M	N/A	80
NKTX Nkarta	3.5558 of 5 stars	$3.67 +8.6%	$10.75 +192.9%	+34.4%	$262.55M	N/A	N/A	140
ACIU AC Immune	2.2099 of 5 stars	$2.52 -0.8%	$7.50 +197.6%	+10.6%	$256.47M	$3.70M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BYSI) was last updated on 7/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeyondSpring (BYSI) Competitors

BYSI vs. NAGE, SRZN, NKTX, ACIU, and CHRS

How does BeyondSpring compare to Niagen Bioscience?

Summary

How does BeyondSpring compare to Surrozen?

Summary

How does BeyondSpring compare to Nkarta?

Summary

How does BeyondSpring compare to AC Immune?

Summary

How does BeyondSpring compare to Coherus Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI vs. The Competition

BeyondSpring Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BeyondSpring (BYSI) Competitors

BYSI vs. NAGE, SRZN, NKTX, ACIU, and CHRS

How does BeyondSpring compare to Niagen Bioscience?

Which has stronger valuation & earnings, NAGE or BYSI?

Is NAGE or BYSI more profitable?

Does the media refer more to NAGE or BYSI?

Which has more risk and volatility, NAGE or BYSI?

Do analysts recommend NAGE or BYSI?

Do institutionals & insiders hold more shares of NAGE or BYSI?

Summary

How does BeyondSpring compare to Surrozen?

Does the media favor BYSI or SRZN?

Is BYSI or SRZN more profitable?

Which has more risk & volatility, BYSI or SRZN?

Do insiders & institutionals have more ownership in BYSI or SRZN?

Which has better earnings and valuation, BYSI or SRZN?

Do analysts rate BYSI or SRZN?

Summary

How does BeyondSpring compare to Nkarta?

Is NKTX or BYSI more profitable?

Do analysts rate NKTX or BYSI?

Do insiders and institutionals believe in NKTX or BYSI?

Which has preferable valuation & earnings, NKTX or BYSI?

Which has more risk and volatility, NKTX or BYSI?

Does the media favor NKTX or BYSI?

Summary

How does BeyondSpring compare to AC Immune?

Is ACIU or BYSI more profitable?

Which has better valuation & earnings, ACIU or BYSI?

Which has more risk and volatility, ACIU or BYSI?

Do insiders & institutionals believe in ACIU or BYSI?

Do analysts prefer ACIU or BYSI?

Does the media refer more to ACIU or BYSI?

Summary

How does BeyondSpring compare to Coherus Oncology?

Do analysts prefer BYSI or CHRS?

Which has more volatility and risk, BYSI or CHRS?

Which has stronger valuation & earnings, BYSI or CHRS?

Does the media favor BYSI or CHRS?

Is BYSI or CHRS more profitable?

Do insiders and institutionals believe in BYSI or CHRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI vs. The Competition

BeyondSpring Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools